Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignacio Matos

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
The British Journal of Surgery|February 21, 2024
Survival and safety after neoadjuvant chemotherapy or upfront surgery for locally advanced colon cancer: meta-analysisDaniel Aliseda, Jorge Arredondo, Carlos Sánchez-Justicia, et al.
Nature Reviews. Cancer|December 7, 2023
Fcγ receptors and immunomodulatory antibodies in cancerFelipe Galvez-Cancino, Alexander P Simpson, Cristobal Costoya, et al.
The Oncologist|May 26, 2018
Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR StudyJaume Capdevila, Alexandre Teulé, Jorge Barriuso, et al.
Biomedicines|August 29, 2024
Neoadjuvant Statistical Algorithm to Predict Individual Risk of Relapse in Patients with Resected Liver Metastases from Colorectal CancerÁngel Vizcay Atienza, Olast Arrizibita Iriarte, Oskitz Ruiz Sarrias, et al.
Nature Cancer|October 27, 2022
Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signalingIdo Yofe, Tomer Landsberger, Adam Yalin, et al.
The Lancet. Respiratory Medicine|April 9, 2021
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 studyTimothy A Yap, Kazuhiko Nakagawa, Nobukazu Fujimoto, et al.
Future Oncology (London, England)|November 3, 2016
Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experienceGuillermo Crespo, Paula Jiménez-Fonseca, Ana Custodio, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 12, 2025
Definition of lines of treatment in metastatic colorectal cancer: a Delphi consensusPilar García-Alfonso, Julia Alcaide-Garcia, Enrique Aranda Aguilar, et al.
Theranostics|January 29, 2026
Autocrine activity of engineered IL-33 mRNA enhances adoptive T-cell therapy for peritoneal carcinomatosis and synergizes with IL-12 mRNALeire Arrizabalaga, Claudia Augusta Di Trani, Celia Gomar, et al.
Molecular Cancer Therapeutics|September 22, 2019
Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION TrialJaume Capdevila, Ignacio Matos, Francesco M Mancuso, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
The British Journal of Surgery|February 21, 2024
Survival and safety after neoadjuvant chemotherapy or upfront surgery for locally advanced colon cancer: meta-analysisDaniel Aliseda, Jorge Arredondo, Carlos Sánchez-Justicia, et al.
Nature Reviews. Cancer|December 7, 2023
Fcγ receptors and immunomodulatory antibodies in cancerFelipe Galvez-Cancino, Alexander P Simpson, Cristobal Costoya, et al.
The Oncologist|May 26, 2018
Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR StudyJaume Capdevila, Alexandre Teulé, Jorge Barriuso, et al.
Biomedicines|August 29, 2024
Neoadjuvant Statistical Algorithm to Predict Individual Risk of Relapse in Patients with Resected Liver Metastases from Colorectal CancerÁngel Vizcay Atienza, Olast Arrizibita Iriarte, Oskitz Ruiz Sarrias, et al.
Nature Cancer|October 27, 2022
Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signalingIdo Yofe, Tomer Landsberger, Adam Yalin, et al.
The Lancet. Respiratory Medicine|April 9, 2021
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 studyTimothy A Yap, Kazuhiko Nakagawa, Nobukazu Fujimoto, et al.
Future Oncology (London, England)|November 3, 2016
Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experienceGuillermo Crespo, Paula Jiménez-Fonseca, Ana Custodio, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 12, 2025
Definition of lines of treatment in metastatic colorectal cancer: a Delphi consensusPilar García-Alfonso, Julia Alcaide-Garcia, Enrique Aranda Aguilar, et al.
Theranostics|January 29, 2026
Autocrine activity of engineered IL-33 mRNA enhances adoptive T-cell therapy for peritoneal carcinomatosis and synergizes with IL-12 mRNALeire Arrizabalaga, Claudia Augusta Di Trani, Celia Gomar, et al.
Molecular Cancer Therapeutics|September 22, 2019
Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION TrialJaume Capdevila, Ignacio Matos, Francesco M Mancuso, et al.
Pageof 4